Skip to main content
Top
Published in: Supportive Care in Cancer 4/2020

01-04-2020 | Constipation | Original Article

More opioids, more constipation? Evaluation of longitudinal total oral opioid consumption and self-reported constipation in patients with cancer

Authors: Eric J. Roeland, Christopher J. Sera, Joseph D. Ma

Published in: Supportive Care in Cancer | Issue 4/2020

Login to get access

Abstract

Purpose

Opioid-induced constipation (OIC) is a distressing physical symptom for patients with cancer taking opioids. Total opioid consumption may contribute to developing worsening OIC-related symptoms. We completed a retrospective analysis examining the association of total daily opioid consumption on self-reported constipation in patients with cancer.

Methods

In over 5 clinic visits, we collected self-reported constipation scores and 24-h oral morphine equivalents (OME). We examined the association between OME and the presence of constipation (i.e., score > 3) and the relationship of OME between patients with or without constipation.

Results

Of 297 patients with cancer, we observed 57.8% with constipation and 42.4% without constipation at the first clinic visit. Age was similar in both groups (54.2 ± 14.5 vs. 56.4 ± 14.8 years [mean ± SD]) and the majority of patients were women (63.7% vs. 61.1%). The most common cancer type in patients with constipation was non-colorectal gastrointestinal (n = 25, 14.6%), while in patients without constipation was colorectal gastrointestinal (n = 25; 19.8%). Across visits, we observed weak or no association between OME and self-reported constipation (r = 0.01–0.27). At the first visit, higher mean OME was seen in patients who self-reported constipation (133.4 vs 76; p < 0.05). Age, sex, metastatic disease, and stimulant laxative use were not associated with constipation.

Conclusions

We observed weak to no association between OME and constipation in patients with cancer. These results suggest a lack of a clear association between total opioid consumption and self-reported constipation.
Literature
5.
go back to reference Veiga, D. R., Mendonca, L., Sampaio, R., Lopes, J. C., & Azevedo, L. F. (2018). Incidence and health related quality of life of opioid-induced constipation in chronic noncancer pain patients: a prospective multicentre cohort study. Pain Res Treat, 2018, 5704627. doi:https://doi.org/10.1155/2018/5704627, 1, 11CrossRef Veiga, D. R., Mendonca, L., Sampaio, R., Lopes, J. C., & Azevedo, L. F. (2018). Incidence and health related quality of life of opioid-induced constipation in chronic noncancer pain patients: a prospective multicentre cohort study. Pain Res Treat, 2018, 5704627. doi:https://​doi.​org/​10.​1155/​2018/​5704627, 1, 11CrossRef
6.
go back to reference Thorpe DM (2001) Management of opioid-induced constipation. Curr Pain Headache Rep 5(3):237–240CrossRef Thorpe DM (2001) Management of opioid-induced constipation. Curr Pain Headache Rep 5(3):237–240CrossRef
10.
go back to reference Neefjes EC, van der Vorst MJ, Boddaert MS, Zuurmond WW, van der Vliet HJ, Beeker A, van den Berg HP, van Groeningen CJ, Vrijaldenhoven S, Verheul HMW (2014) Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone. BMC Palliat Care 13:42. https://doi.org/10.1186/1472-684X-13-42 CrossRefPubMedPubMedCentral Neefjes EC, van der Vorst MJ, Boddaert MS, Zuurmond WW, van der Vliet HJ, Beeker A, van den Berg HP, van Groeningen CJ, Vrijaldenhoven S, Verheul HMW (2014) Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone. BMC Palliat Care 13:42. https://​doi.​org/​10.​1186/​1472-684X-13-42 CrossRefPubMedPubMedCentral
11.
go back to reference Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9CrossRef Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9CrossRef
17.
go back to reference Goodin S, Cunningham R (2002) 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist 7(5):424–436CrossRef Goodin S, Cunningham R (2002) 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist 7(5):424–436CrossRef
18.
go back to reference Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16(2):754–760. https://doi.org/10.1200/JCO.1998.16.2.754 CrossRefPubMed Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16(2):754–760. https://​doi.​org/​10.​1200/​JCO.​1998.​16.​2.​754 CrossRefPubMed
Metadata
Title
More opioids, more constipation? Evaluation of longitudinal total oral opioid consumption and self-reported constipation in patients with cancer
Authors
Eric J. Roeland
Christopher J. Sera
Joseph D. Ma
Publication date
01-04-2020
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 4/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04996-7

Other articles of this Issue 4/2020

Supportive Care in Cancer 4/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine